Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Osteosarcoma
Stage/Subtype:  metastatic osteosarcoma
Trial Type:  Treatment
Results 1-25 of 27 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: AWACMOS1102, NCI-2013-01371, ACORN AWACMOS1102, NCT01759303
Hypofractionated Stereotactic Radiation Therapy in Treating Younger Patients with Metastatic Sarcomas of Bony Sites
Status: Active
Phase: Phase II
Type: Treatment
Age: Greater than 3 to less than or equal to 40
Trial IDs: J1367, NCI-2013-02433, NA_00070109, NCT01763970
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, NA_00076243, CIR00009228, CIR00008429, NCT01804634
Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients with Metastatic Sarcoma Stable on Chemotherapy
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201309108, NCI-2013-01842, NCT01986829
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Cabozantinib-s-malate in Treating Patients with Relapsed Osteosarcoma or Ewing Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: 9620, NCI-2014-01927, CABONE, NCT02243605
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Metastatic Soft Tissue and Bone Sarcomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14S03, NCI-2014-02583, STU00200112, NCT02357810
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, UPCI #10-027, REN13120042, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Dinutuximab in Combination with Sargramostim in Treating Patients with Recurrent Osteosarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 29 and under
Trial IDs: AOST1421, NCI-2015-01001, NCT02484443
Denosumab in Treating Patients with Recurrent or Refractory Osteosarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 11 to 49
Trial IDs: AOST1321, NCI-2015-00543, NCT02470091
Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Sarcoma That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091401, NCI-2015-00260, NCT02500797
Durvalumab and Tremelimumab in Treating Patients with Metastatic or Refractory Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-1071, NCI-2016-01178, NCT02815995
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Recurrent or Refractory Tumors in the Brain and/or Spinal Cord
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: 03-133, NCI-2016-00928, MSKCC-03133, NCT00089245
HER2-Specific T Cells in Treating Patients With HER2-Positive Refractory or Metastatic Sarcoma
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: HEROS, NCI-2012-00634, NCT00902044
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 20 years
Trial IDs: SPOC-2012-001, NCI-2014-02681, NCT02013336
T Cell Receptor Gene Therapy in Treating Younger Patients with Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 35 and under
Trial IDs: 14-C-0059, NCI-2014-02506, P131369, NCT02107963
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Proton Beam Radiation Therapy in Treating Younger Patients with Bone or Non-rhabdomyosarcoma Soft Tissue Sarcomas
Status: Active
Phase: No phase specified
Type: Treatment
Age: 30 and under
Trial IDs: 05-326, NCI-2012-00673, NCT00592293
Prolonged Duration Methotrexate, Doxorubicin Hydrochloride, and Cisplatin with or without Pantoprazole Sodium in Reducing or Preventing Chemotherapy Induced Kidney Damage and Hearing Loss in Younger Patients with Previously Untreated Osteosarcoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 1 to 29
Trial IDs: CHP12ST051, NCI-2014-01661, 12ST051, 13-009967, CHP12ST051 OS Pilot, NCT01848457
Start Over